Novartis/Hexal – Lessons for the Generics Industry

Abstract

The acquisition of Hexal by Novartis holds a number of lessons for the generics industry, but it is not clear whether Hexal's peers are drawing the correct conclusions. The deal may give the impression that generic drug assets are very valuable, but a better interpretation might be that times are tough even for the biggest companies and that smart management is what the industry needs most.